Document VJDRL80ovBQe4krRQZzd6Ge94

VC- MANUFACTURING CHEMISTS ASSOCIATION Iti'j Gl-NNI criCUT AVENUt'.. N W WASHINGTON. D.C .'0009 (20?) -103-0126 \Q~\o-~)f September 27, 1974 To; Technical Task Group on Vinyl Chloride Research Subject: Conference with Rail Committee re Vinyl Chloride Research Gentlemen: Distributed herewith are copies of Dr. V. K. Rowe's notes on the subject conference. MCA has, by telephone, ex pressed to Dr. Wands its support of the coordination center proposal, and of its willingness to cooperate in its activi ties . Sincerely, 2 . t / / r r w ^r Kenneth D. Johnson, Ph.D. Secreta ry Technic al Task Group on Vinyl Chloride Research KDj/mb Enclosure cc: Mr. A. W. Barnes D. P, Duffield, M.D. Dr. Tiziano Garlanda CUSAROSS 02079 MEMORANDUM to See Below DEBAR I N'.I N F OF UFAl-TM. EDI MAHON, ANu '.>!! I'O!'! 1C IILM III Mill ICE SUIO'H I, A1 1 I M / S < > J III 4 1 Iff National Institute of Environmental Health Scienc n.Mii September 5, 1974 from Director, NIEHS suniECT Vinyl Chloride Meeting of August 14, 1974 Enclosed are the notes which V. K. Rowe took at our Vinyl Chloride meeting in Washington, D. C. on August 14, 1974. I discussed the concept of sotting up an NAS-NRC clearing house effort in Vinyl Chloride with the HEW Toxicology Coordinating Committee. The Committee endorsed this concept. Next day Drs. Shapiro and Plumlee contacted Dr, Ralph Wands informally and he seemed agreeable. It appears, therefore, that the next step is for me to write Dr. Handler with a formal request, which I shall do. , Addressees: Dr. Nancy Beech Dr. A. Pallottta Dr. L. Plumlee Dr. R. Shapiro Kusnetz Dr. M. Littlefield Pr. E. Fairchild Dr. M. Mehlman Dr. I. Mitchell ^ David P. Rail, M.D., Ph.D. T CUSAROSS 02080 VINYL CHLORIDE MON CM FIT--NOTES FROM /'\! AD HOC MEETING CONCERNED WITH REGEnRCH PROGRAM COORDINATION Tho mooting k,:g hold August 14 , 1974 , in the Potonne of the Marriott Twin j'rideos Motel, Wnr.hington. D (.. purpose of uhe rv-of. ing war. to discuss means l'y whi oh groups interested in to::ico 1 oqioa 1 research on vinyl monomer (VCMl could develop a coordinated program. Loon The. v,ii-;.cuc cb..loci''e Attendear: V.^A Or. Haney Leech Dr. A. PalJuttta IN;. L ,, Plum Ice NCTR Dr. M. Littlefield NT EPS Dr. R. Shapiro MCA Mr. 1!. Kur-notz (Vinyl Chloride Tox. Coinni tL ac Member) .Dr. Davie Rail MI OSH Dr. E. Fairchild Tho Dow Chemical Company Dr. V. K. Rowe Tho mooting was called to order at 3:10 PM by V. l\. Rowe on behalf of Chairman Rail who had asked that we proceed as ho, would be a bit late. Dr. Pallotta, who had just returned from Europe where he had visited Dr. Maltcni's laboratory, reported that this laboratory was superb. He said that he had not seen a finer laboratory anywhere and that the conduct of the experiments in progress and the records being kept were above reproach. Dr. rallctta's judament was based upon seeing but one of Dr. Maltoni's four operating laboratories. He indicated that a new laboratory is being built inside cf an. eld pc? ace v:hich the Italian Government apparently had given to Dr. Maltnni for bis work. Dr. Pallotta indie a tod. that Dr. Mai ton! has observed an angiosarcoma of the liver in one of the hamstenrs exposed to 500 ppm VC? ; is conducting CUSAROSS 02081 . . o4 . ' V *t ^ ,:v. experiment in which old"animals arc being exposr.d to V'.JM; <i d ho j c f; -'ud v"* j ;:q another ruonomor r. tno" i dent tv*" *of which wrot. o'1v-cj ns of . i'h.noiro s to hod that he was certain ; lri1 oral r-tulior :`iro.h'infl the ado ini strut ion of VCM i.n olive oil wore be -.ryj or-nriuoted. at Dr, Holton's laboratory and also at; 1 shorn tor io; in the Mother land e and. ruyj.md. ,, f!e wasn't positive th1'~-f those, cyrerimenhs v/cre underway, `nut if ;v'h. they were 1 o bn varted soon. : was ashed i.o on11 L.ne Hu purpose of the meet;i i y. Inn rbihod the'; the VI..'?. problem is fonyc,' inn: Iviug mr' ` an. . . x of a ova runic ratIndustv5 nr, anf uni versi ties and its no- r>.; : n wc::l d.wido,. He reels that; resmj.r-h is liJely in or e inuo in no in. all i j rent*, ions hoc:-" use there is -o one c: .vf n ' mi -rrn- !..; nn e.oi"d-"`.e, ft scorns reasoned]o to as t i ei on o that aoonoivs ,, CT1ii` arlv Jivnc-ire a.oe.nricn t will hr: heroigod with rogue for yr ants for cor:tracts to do toxicolcoiccl v.'nri: of one: hind. f or another or>. VC?!. The aycnlcos iuive no vary, at tho present time, of knowing whether such work is already being cone. ?ho scire situation appJ.ies to 5 ndu?:hria3. research Icborctcr j.ov and industrial, croups seeking to sponsor studios at; outside la.bora.tori os, Rowe foe3.io.vo;'.> tnat there is a need for cooi'din j. t?on. of research which is foc-*ii;c conducted, on such a largo conic in many p3.eccs within cad outsi.de of th.o U.S.A. tu.oh a r ~iord .inciting ofn3.ee ini.cht well, for- ro t-uo to collect prcl.ccc.:. i ron various invest j.oa.tors. release date as scon as it is rcud.v ,nnd to l;c'ep track 3 nten. l..icn:j o: various w.-^ups o: etchers, T.t wou3.d then foe possifoje for anyone planning to do j:esc arch on VCM to find out what v;?s foei n-.j done, vi'ese it wn n foe inn d.cno and d'-t whom. duch a con'or would, most re-r t.a: r, 3 v not liave on'.' pov;or of J : roe hi. or but would, provide, a form wbcrebv i t v/cu3.d. foe pos sih3 e lor a group ho not CUSAROSS 02082 -3- unwittingly duplicate research which was complete or under way. Furthermore, it would permit researchers to inquire and discuss the programs in progress prior to starting programs of their own. Programs could then be designed to duplicator for purposes of confirmation or to complement studies underway. Rowe believes this i.s the only way in which we can avoid wastefulness. Consequently,such a clearing house should enhance the acquisition of knowledge so badly needed. It was also pointed out that such a clearing house could assume the leadership in calling conferences of interested researchers and thorebv assist in the dissemination of information. There seemed to be no opposition to the program and, in fart, there was unanimous agreement that such a coordination center should be developed. The discussion began about how and 'where the objectives could be accomplished. . Dr. Plumlee stated that there was precedent for such a clearing house. He stated that the late Dr. Leo Friedman of FDA and Dr. Ned Byerly of USDA had set-up a similar group concerned with the nitrocamines. He felt that this particular group had been very effective in enhancing com munications between researchers concerned with the problem. Dr. Lassiter thought that perhaps one of the groups under 4 the ILO could be used. Mr. Kusnetz thought that there might be possibilities within the EEC. Dr. Plumlee mentioned that the NCI could probably help and Dr. Pallotta emphatically agreed. Dr. Lassiter also mentioned that the Internetion? J. Aqency for Research on Cancer ( IARC ) hearquartered at Lyon, France might also serve since they are already collecting and coordinating worldwide efforts on cancer research. CUSAROSS 02083 Dr. ra llotta suggested that perhaps Ralph Wands, Advisory Cantor on Tori cologv in the NAS/NRC could cffectivply do the job. Dr. Shapiro pointed out that Mr. Wands' office would have the moans of interfacing with the Europeans and others as well as coordinating any work in the U.S.A. Dr. Rail reported that Dr. Rrant Dietrich, Head of Environmental and Occupational Health of WHO might also be willing to help. f'Jie suggestion that .Ralph Wands' office be the coordinating office received unanimous support. A recess was called and Dr,. Shapiro called Ralph Wands to see if it would be feasible for his office to undertake such a coordinating job. Wands indicated that ho would be willing, that there was no question cf feasibility and that the agencies or groups involved would have to having a working contract with NAS/NRC, He mentuofed that funding would be required and. details of this could bo worked out. This proposal seemed to meet with the approval of the entire group assembled. t The next question considered was what agency or groups should be asked to sponsor the contract with the NAS/NRC? Several possibilities were mentioned, the ONR which already has a big contract with the Academy, the N5F, EPA, FDA, NIEHS, OSHA, and DGL were also mentioned as possibilities. It was agreed, however, that a group or agency having little or no politicalinterest in the VCM problem would probably'be the best, for it would provide an umbrella under which all of the interested parties could work together. Dr. Fairchild noted that any single agency could go directly to the NAS/NRC and industry could do likewise. However, it seemed to be the consensus that it would bo bettor if they could go "piggy-back" on an existing contract such as that hold by the NSF. CUSAROSS 02084 -5- Chairman Rail appointed Dr. Shapiro and Dr. Plumleo to contact Ralph Wands as soon as possible and see what needed to be done and report back to him. Dr. Rail will explore the problem of funding and the associated political problems. When he receives a report from Shapiro and Plumlce, he will report to the group. The question was raised as to what research the various agencies represented had planned. Dr. Plumlee stated that EPA was planning a teratology study. Rowe informed the group that Dow had essentially completed such a study and that information would be made available. Rowe suggested that Plumlee contact Dr. Perry Gehring of Dow directly for details of the work in progress. Plumlee also indicated that they were planning some studies to measure co-stresses of ethyl alcohol, vinylidene chloride and nutritional factors upon toxicological effects induced by vinyl chloride. Dr. Rail stated that NIEIIS had two projects which they were considering; one. Dr. Drew of his laboratory is going to prepare tissues from animals exposed to VC1 for Dr. Hans Popper to study, and two, NIEIIS c is hoping to enhance Dr. Solikoff's work in the epidemiological area. Dr. Fairchild indicated that they had not planned any further research since they felt, as the group assembled did, that before starting further toxicological studies they should know what is presently being done. He did indicate that they were continuing to support the epidemiological work that they had already started. Dr. Shapiro said that the FDA had no plans at the moment. Dr. Rail asked Rowe if he would summarize his notes of the meeting for distribution through the Chairman. Rowe agreed. Chairman Rail then adjourned the meeting at approximately 6 PM. Respectfully submitted, V. K. Rowe, Acting Secretary Dow Chemical U.S.A. IP03 Building Midland, Michigan 45540 CUSAROSS 02085